THERE was a time when the biggest questions surrounding athletes and weight loss were straightforward: How much weight should an athlete lose? How quickly? And at what point does getting lighter stop helping performance and start hurting it?
GLP-1 medications have complicated that conversation.
Drugs such as semaglutide have moved from being relatively specialised medical treatments to becoming part of a much larger cultural conversation about body weight, appetite and health. Now elite sport is having to work out where these medications fit.
The answer, at least for now, is that they are legal.
That distinction matters.
The World Anti-Doping Agency currently does not prohibit GLP-1 agonists. Semaglutide has, however, been placed on WADA’s monitoring programme, meaning its use in sport is being observed and evaluated rather than treated as an anti-doping violation. The US Anti-Doping Agency likewise says athletes do not currently need a Therapeutic Use Exemption to use a GLP-1 medication.
But the fact that something is permitted does not end the sporting debate. In some ways, it begins it.
Weight is not the same thing as performance
This is where the discussion can become unnecessarily simplistic.
An athlete who loses weight is not automatically gaining a competitive advantage. In many sports, body composition matters enormously, but the relationship between body weight and performance depends on the event, the athlete and how that weight was lost.
A distance runner, gymnast, cyclist, wrestler, boxer or combat-sport athlete may have very different reasons for wanting to reduce body weight. A professional tennis player has a different set of physical demands from a powerlifter. A swimmer has different requirements from a marathon runner.
And then there is the question of what the athlete actually loses.
If a medication helps an athlete reduce excess body fat while maintaining strength, muscle mass and adequate nutrition, the sporting consequences may be very different from an athlete who simply becomes lighter while losing muscle and compromising recovery.
That makes the phrase ‘performance-enhancing drug’ particularly complicated in this context.
GLP-1 medications are not designed to build muscle, increase oxygen-carrying capacity or directly stimulate explosive power. Their principal effects include reducing appetite, slowing gastric emptying and affecting insulin regulation.
Any sporting advantage, therefore, would potentially be indirect.
And that is precisely what makes the anti-doping question so difficult.
Should an indirect advantage be treated differently?
Sport has traditionally been concerned with substances that directly alter athletic performance.
Steroids can increase muscle mass and strength. Blood doping can increase oxygen delivery. Certain stimulants can affect alertness and exertion.
GLP-1 medications occupy a different space.
Suppose an athlete has obesity or another legitimate medical indication and treatment allows that athlete to reach a healthier body composition. Is that fundamentally different from an athlete without the same medical need taking the medication primarily to become lighter?
The medication is identical. The circumstances are not.
That distinction is likely to become central to the debate.
Anti-doping authorities cannot simply ask whether a drug makes athletes better. Almost any effective medical intervention could potentially affect performance in some way. The harder question is whether the substance produces a type or degree of advantage that sport considers incompatible with fair competition.
WADA’s monitoring approach suggests that the organisation is still gathering information rather than having reached that point with GLP-1s.
Serena Williams entering this discussion gives the subject an unusual dimension.
Williams does not need an introduction to the world of elite sport. Her career provides a useful reminder that athletes are not simply performance machines. They are people whose bodies change with age, injury, pregnancy, retirement and life outside competition.
That matters because much of the public discussion about GLP-1 medications is still framed around appearance.
Elite sport should be more interested in physiology.
If a retired or returning athlete discusses weight-loss medication, the important questions are not simply whether that person became thinner. The questions are whether the medication affected training capacity, recovery, muscle retention, nutrition and competitive performance.
Those are considerably more difficult questions to answer.
And they require evidence rather than assumptions.
There is another side to the equation
There is also a danger in treating GLP-1 medications as harmless simply because they are currently permitted.
USADA has specifically warned athletes about unapproved products sold online and through social media. The agency notes concerns about products with inaccurate ingredients, inappropriate dosing and other safety issues.
For athletes, that is especially important.
An elite competitor cannot afford to treat medication like a casual supplement.
Athletes are ultimately responsible for what is in their systems under anti-doping rules. USADA also recommends checking the anti-doping status of medications before use.
So even if GLP-1s remain legal, the surrounding ecosystem of counterfeit, compounded or otherwise unapproved products could create a completely different problem.
The bigger problem may be the culture around weight
Perhaps the most uncomfortable part of this debate has little to do with doping.
Athletes have always operated under enormous pressure concerning body weight.
Gymnasts have been expected to remain extremely light. Distance runners have sometimes been encouraged to chase ever-lower body weights. Combat-sport athletes cut weight to make divisions. Athletes in appearance-based sports face another kind of pressure altogether.
GLP-1 medications potentially make it easier to manipulate body weight.
That does not automatically make their use unethical. But it does raise questions about whether athletes are going to feel increasingly compelled to use medication simply because other athletes are using it.
That is a very different problem from deliberate doping.
If the competitive environment eventually becomes one in which an athlete believes, ‘I have to take this because everyone else is taking it,’ the issue becomes less about individual choice and more about competitive pressure.
Sport has encountered that problem before.
A ban would not necessarily solve everything.